Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Aftaid; Aphthasol; Aptheal; Apthera; CHX 3673; Miraftil; OraDisc A; OraRinse™

Latest Information Update: 13 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Pharmascience; ULURU
  • Class Aminopyridines; Anti-inflammatories; Antiallergics; Antiulcers; Small molecules
  • Mechanism of Action Histamine release inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Aphthous stomatitis

Highest Development Phases

  • Market Withdrawal Aphthous stomatitis
  • Discontinued Atopic dermatitis; Mouth disorders; Mucositis

Most Recent Events

  • 05 Jul 2017 Amlexanox topical patch (OraDisc™ A) is available for licensing in USA as of 05 Jul 2017. https://www.uluruinc.info/
  • 05 Aug 2016 Meda has been acquired by Mylan
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top